J. Agnholt

发表

Complement Activation Mediated by Mannan‐Binding Lectin in Plasma from Healthy Individuals and from Patients with SLE, Crohn's Disease and Colorectal Cancer. Suppressed Activation by SLE Plasma

G. Baatrup, S. Svehag, O. Thorlacius-Ussing, 2002, Scandinavian journal of immunology.

Infliximab downregulates interferon-gamma production in activated gut T-lymphocytes from patients with Crohn's disease.

K. Kaltoft, J. Agnholt, J∅rgen Agnholt, 2001, Cytokine.

Osteopontin, a Protein with Cytokine‐like Properties, is Associated with Inflammation in Crohn's Disease

J. Dahlerup, L. Schack, C. Hvas, 2007, Scandinavian journal of immunology.

Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease

E. Lundorf, J. Agnholt, S. Buntzen, 2003, Alimentary pharmacology & therapeutics.

Clinical trial: vitamin D3 treatment in Crohn’s disease – a randomized double‐blind placebo‐controlled study

J. Kelsen, L. A. Christensen, J. Dahlerup, 2010, Alimentary pharmacology & therapeutics.

Adalimumab treatment in Crohn's disease does not induce early changes in regulatory T cells

J. Dahlerup, C. Hvas, B. Deleuran, 2011, Scandinavian journal of gastroenterology.

Long‐term effect of medical treatment of diarrhoea in 377 patients with SeHCAT scan diagnosed bile acid malabsorption from 2003 to 2016; a retrospective study

J. Dahlerup, K. Krogh, S. M. Jørgensen, 2018, Alimentary pharmacology & therapeutics.

111Indium‐labelled human gut‐derived T cells from healthy subjects with strong in vitro adhesion to MAdCAM‐1 show no detectable homing to the gut in vivo

H. Hoffmann, J. Kelsen, L. Falborg, 2004, Clinical and experimental immunology.

The effect of etanercept and infliximab on the production of tumour necrosis factor alpha, interferon-gamma and GM-CSF in in vivo activated intestinal T lymphocyte cultures.

J. Dahlerup, K. Kaltoft, J. Agnholt, 2003, Cytokine.

The effect of etanercept and infliximab on the production of tumour necrosis factor α, interferon-γ and GM-CSF in in vivo activated intestinal T lymphocyte cultures

J. Dahlerup, K. Kaltoft, J. Agnholt, 2003 .

FoxP3+CD4+CD25+ T cells with regulatory properties can be cultured from colonic mucosa of patients with Crohn's disease

J. Dahlerup, C. Hvas, J. Kelsen, 2005, Clinical and Experimental Immunology.

from colonic mucosa of patients with Crohn's disease

J. Dahlerup, C. Hvas, H. Hoffmann, 2005 .

The lectin pathway of the complement system is downregulated in Crohn's disease patients who respond to anti-TNF-α therapy.

S. Thiel, J. Dahlerup, T. Sandahl, 2014, Journal of Crohn's & colitis.

Plasma prekallikrein as a prognostic indicator in chronic liver insufficiency.

J. Dyerberg, S. Rasmussen, J. Møller-Petersen, 1990, Scandinavian journal of gastroenterology.

T-cell vaccination in Crohn's disease: principles and presentation of the first two cases.

J. Dahlerup, K. Kaltoft, J. Agnholt, 2002, Cytokines, cellular & molecular therapy.

Macrophage and dendritic cell subsets in IBD: ALDH+ cells are reduced in colon tissue of patients with ulcerative colitis regardless of inflammation

L. Öhman, M. Magnusson, S. Gudjonsson, 2015, Mucosal Immunology.

Crohn's disease intestinal CD4+ T cells have impaired interleukin-10 production which is not restored by probiotic bacteria

J. Dahlerup, P. Höllsberg, C. Hvas, 2007, Scandinavian journal of gastroenterology.

Increased expression of TCR Vβ5.1 and 8 in mucosal T‐cell Lines cultured from patients with Crohn disease

J. Dahlerup, H. Hoffmann, J. Kelsen, 2004, Scandinavian journal of gastroenterology.

High-dose vitamin D3 supplementation decreases the number of colonic CD103+ dendritic cells in healthy subjects

L. Reinert, M. Magnusson, J. Agnholt, 2018, European Journal of Nutrition.

Active Crohn's disease is associated with low vitamin D levels.

L. A. Christensen, J. Dahlerup, C. Hvas, 2013, Journal of Crohn's & colitis.

1,25-dihydroxyvitamin D3 and dexamethasone increase interleukin-10 production in CD4+ T cells from patients with Crohn's disease.

J. Dahlerup, C. Hvas, J. Kelsen, 2007, International immunopharmacology.

Letter: long‐term treatment of severe bile acid diarrhoea—obeticholic acid can normalise SeHCAT retention. Authors’ reply

J. Dahlerup, K. Krogh, S. M. Jørgensen, 2018, Alimentary pharmacology & therapeutics.

Safety and efficacy of infliximab and corticosteroid therapy in checkpoint inhibitor‐induced colitis

M. Donia, I. Svane, J. Seidelin, 2022, Alimentary pharmacology & therapeutics.

In situ Activated Intestinal T Cells Expanded in vitro – without Addition of Antigen – Produce IFN-γ and IL-10 and Preserve Their Function during Growth

K. Kaltoft, J. Agnholt, 2002, Experimental and Clinical Immunogenetics.

Spondylitis-psoriasis-enthesitis-enterocolitis-dactylitis-uveitis-peripheral synovitis (SPEED-UP) treatment.

L. Iversen, I. McInnes, A. Loft, 2020, Autoimmunity reviews.

Flow cytometry detection of vitamin D receptor changes during vitamin D treatment in Crohn's disease

J. Dahlerup, B. Deleuran, L. Husted, 2015, Clinical and experimental immunology.

Human dendritic cell antigen presentation and chemotaxis are inhibited by intrinsic 25-hydroxy vitamin D activation.

J. Dahlerup, C. Hvas, J. Agnholt, 2010, International immunopharmacology.

Vitamin D increases programmed death receptor-1 expression in Crohn’s disease

J. Dahlerup, C. Hvas, B. Deleuran, 2017, Oncotarget.

Severe steroid refractory gastritis induced by Nivolumab: A case report

H. Schmidt, M. Nielsen, J. Agnholt, 2020, World journal of gastroenterology.

Efficacy of Injection of Freshly Collected Autologous Adipose Tissue Into Perianal Fistulas in Patients With Crohn's Disease.

K. Krogh, M. Kassem, H. Hougaard, 2019, Gastroenterology.

Differential modulation of p38 mitogen activated protein kinase and STAT3 signalling pathways by infliximab and etanercept in intestinal T cells from patients with Crohn's disease.

P. Rosenstiel, D. Seegert, G. H. Waetzig, 2005, Gut.

Oral vitamin D3 supplementation reduces monocyte-derived dendritic cell maturation and cytokine production in Crohn’s disease patients

J. Dahlerup, C. Hvas, J. Agnholt, 2014, Inflammopharmacology.

25-Hydroxy vitamin D3 modulates dendritic cell phenotype and function in Crohn’s disease

J. Dahlerup, C. Hvas, J. Agnholt, 2013, Inflammopharmacology.

Effects of Anti-TNFα Treatment on Mucosal Expression of IL-17A, IL-21, and IL-22 and Cytokine-Producing T Cell Subsets in Crohn's Disease

L. Öhman, J. Dahlerup, M. Magnusson, 2018, Mediators of inflammation.

Casein glycomacropeptide for active distal ulcerative colitis: a randomized pilot study

L. A. Christensen, J. Dahlerup, C. Hvas, 2016, European journal of clinical investigation.

Soluble CD163, a Specific Macrophage Activation Marker, is Decreased by Anti‐TNF‐α Antibody Treatment in Active Inflammatory Bowel Disease

H. Møller, J. Dahlerup, H. Grønbæk, 2014, Scandinavian journal of immunology.

CARDIAC HYPERSENSITIVITY TO 5-AMINOSALICYLIC ACID

C. Gøtzsche, S. Rasmussen, J. Agnholt, 1989, The Lancet.

Increased production of granulocyte–macrophage colony-stimulating factor in Crohn's disease – a possible target for infliximab treatment

J. Dahlerup, J. Kelsen, J. Agnholt, 2004, European journal of gastroenterology & hepatology.

Considerable variation in the concentration of osteopontin in human milk, bovine milk, and infant formulas.

L. Schack, B. Christensen, J. Kelsen, 2009, Journal of dairy science.

Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn’s Disease Patients Treated with High-Dose Vitamin D Alone or Combined with Infliximab

B. Bibby, J. Dahlerup, B. Deleuran, 2020, Nutrients.

Paediatric Crohn’s Disease Patients Have Increased Inflammatory Markers Compared to Adult Patients prior to Biological Treatment

M. Malham, V. Wewer, J. Agnholt, 2022, GastroHep.

Discrete changes in circulating regulatory T cells during infliximab treatment of Crohn's disease

L. A. Christensen, J. Dahlerup, C. Hvas, 2010, Autoimmunity.

Editorial: safety and efficacy of infliximab and corticosteroids in checkpoint inhibitor‐induced colitis—authors' reply

M. Donia, I. Svane, J. Seidelin, 2022, Alimentary pharmacology & therapeutics.

Casein glycomacropeptide is well tolerated in healthy adults and changes neither high-sensitive C-reactive protein, gut microbiota nor faecal butyrate: a restricted randomised trial

T. R. Licht, J. Dahlerup, C. Hvas, 2020, British Journal of Nutrition.

Reduced numbers of mucosal DRint macrophages and increased numbers of CD103+ dendritic cells during anti-TNF-α treatment in patients with Crohn’s disease

L. Öhman, M. Magnusson, M. Wick, 2016, Scandinavian journal of gastroenterology.

The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon

J. Nyengaard, A. Keshavarzian, S. Pillai, 2017, Mucosal Immunology.

Current, experimental, and future treatments in inflammatory bowel disease: a clinical review

J. Dahlerup, C. Hvas, J. Agnholt, 2018, Immunopharmacology and immunotoxicology.

Immune responses and parasitological observations induced during probiotic treatment with medicinal Trichuris suis ova in a healthy volunteer.

J. Dahlerup, L. Iversen, P. Nejsum, 2017, Immunology letters.

Increased levels of circulating Th17 cells in quiescent versus active Crohn's disease.

J. Dahlerup, T. Sandahl, C. Hvas, 2013, Journal of Crohn's & colitis.

Constitutive STAT3 Activation in Intestinal T Cells from Patients with Crohn's Disease*

A. Svejgaard, A. Woetmann, J. Kelsen, 2003, The Journal of Biological Chemistry.

Effectiveness of infliximab treatment of complex idiopathic anal fistulas

A. Nordholm-Carstensen, K. Krogh, H. Hougaard, 2021, Scandinavian journal of gastroenterology.

Motorized spiral enteroscopy: results of an international multicenter prospective observational clinical study in patients with normal and altered gastrointestinal anatomy

M. Neurath, J. Saurin, H. Neuhaus, 2021, Endoscopy.

Vitamin D3 treatment of Crohn’s disease patients increases stimulated T cell IL‐6 production and proliferation

J. Dahlerup, J. Agnholt, L. Bartels, 2010, Alimentary pharmacology & therapeutics.

Toll‐like receptor‐induced granulocyte‐macrophage colony‐stimulating factor secretion is impaired in Crohn's disease by nucleotide oligomerization domain 2‐dependent and ‐independent pathways

P. Rosenstiel, A. Till, P. Höllsberg, 2009, Clinical and experimental immunology.

Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment

A. Drewes, T. Jess, J. Fallingborg, 2019, European journal of gastroenterology & hepatology.

Seven Weeks of High-Dose Vitamin D Treatment Reduces the Need for Infliximab Dose-Escalation and Decreases Inflammatory Markers in Crohn’s Disease during One-Year Follow-Up

B. Bibby, J. Dahlerup, B. Deleuran, 2021, Nutrients.

Complement activation in plasma before and after Infliximab treatment in Crohn disease

G. Baatrup, O. Thorlacius-Ussing, E. Zimmermann-Nielsen, 2003, Scandinavian journal of gastroenterology.

Toxic hepatitis due to femoxetine.

J. Agnholt, N. Aunsholt, 2009, Acta pharmacologica et toxicologica.

Bile acid malabsorption investigated by selenium-75-homocholic acid taurine ((75)SeHCAT) scans: causes and treatment responses to cholestyramine in 298 patients with chronic watery diarrhoea.

L. A. Christensen, J. Dahlerup, L. Gormsen, 2011, European journal of internal medicine.

Effectiveness of interdisciplinary combined dermatology–gastroenterology–rheumatology clinical care compared to usual care in patients with immune-mediated inflammatory diseases: a parallel group, non-blinded, pragmatic randomised trial

L. Iversen, A. Loft, R. Christensen, 2021, BMJ Open.

Delayed hypercalcemia after non-oliguric acute renal failure associated with rhabdomyolysis.

J. Agnholt, P. T. Andersen, L. K. Nielsen, 2009, Acta medica Scandinavica.

[Biological therapy as treatment of inflammatory bowel diseases].

J. Agnholt, 2008, Ugeskrift for læger.

Severe Gastrointestinal Bleeding in a Patient With Subvalvular Aortic Stenosis Treated With Thalidomide and Octreotide: Bridging to Transcoronary Ablation of Septal Hypertrophy

J. Agnholt, S. Poulsen, Helene S. Hvid-Jensen, 2015, Journal of clinical medicine research.

Oral vitamin D3 supplementation reduces monocyte-derived dendritic cell maturation and cytokine production in Crohn’s disease patients

J. Dahlerup, C. Hvas, J. Agnholt, 2014, Inflammopharmacology.

25-Hydroxy vitamin D3 modulates dendritic cell phenotype and function in Crohn’s disease

J. Dahlerup, C. Hvas, J. Agnholt, 2013, Inflammopharmacology.

The occurrence of Helicobacter pylori in the oesophagus

J. Fallingborg, S. Rasmussen, J. Agnholt, 1991 .

Discontinuation of Infliximab Therapy in Patients with Crohn’s Disease

J. Jahnsen, J. Dahlerup, T. Klausen, 2022, NEJM Evidence.